A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL
Open Access
- 17 September 2011
- journal article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 20 (24), 4903-4915
- https://doi.org/10.1093/hmg/ddr428
Abstract
Relapse is a major challenge in the successful treatment of childhood acute lymphoblastic leukemia (ALL). Despite intensive research efforts, the mechanisms of ALL relapse are still not fully understood. An understanding of the molecular mechanisms underlying treatment outcome, therapy response and the biology of relapse is required. In this study, we carried out a genome-wide microRNA (miRNA) microarray analysis to determine the miRNA expression profiles and relapse-associated miRNA patterns in a panel of matched diagnosis-relapse or diagnosis-complete remission (CR) childhood ALL samples. A set of miRNAs differentially expressed either in relapsed patients or at diagnosis compared with CR was further validated by quantitative real-time polymerase chain reaction in an independent sample set. Analysis of the predicted functions of target genes based on gene ontology 'biological process' categories revealed that the abnormally expressed miRNAs are associated with oncogenesis, classical multidrug resistance pathways and leukemic stem cell self-renewal and differentiation pathways. Several targets of the miRNAs associated with ALL relapse were experimentally validated, including FOXO3, BMI1 and E2F1. We further investigated the association of these dysregulated miRNAs with clinical outcome and confirmed significant associations for miR-708, miR-223 and miR-27a with individual relapse-free survival. Notably, miR-708 was also found to be associated with the in vivo glucocorticoid therapy response and with disease risk stratification. These miRNAs and their targets might be used to optimize anti-leukemic therapy, and serve as novel targets for development of new countermeasures of leukemia. This fundamental study may also contribute to establish the mechanisms of relapse in other cancers.This publication has 52 references indexed in Scilit:
- Glucocorticoid use in acute lymphoblastic leukaemiaThe Lancet Oncology, 2010
- Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profilesGenes, Chromosomes and Cancer, 2009
- Oncogenic microRNA‐27a is a target for anticancer agent methyl 2‐cyano‐3,11‐dioxo‐18β‐olean‐1,12‐dien‐30‐oate in colon cancer cellsInternational Journal of Cancer, 2009
- Distinct microRNA expression profiles in acute myeloid leukemia with common translocationsProceedings of the National Academy of Sciences of the United States of America, 2008
- The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA ExpressionMolecular and Cellular Biology, 2008
- MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemiaProceedings of the National Academy of Sciences of the United States of America, 2007
- Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group studyBlood, 2006
- BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological NetworksBioinformatics, 2005
- MicroRNAs Modulate Hematopoietic Lineage DifferentiationScience, 2004
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003